Investor Presentation - First Six Months of 2021

62 Investor presentation First six months of 2021 In STEP 5, people treated with semaglutide 2.4 mg sustained their weight loss over 2 years Clinically relevant and sustained weight loss in patients % change in body weight 0 with obesity or overweight Placebo: -0.6% DI Data from STEP 5 40% of patients lost ≥ 20% of their body weight -6 2 46 ∞ -2 -4 -8 -10 -12 -14 -16 -18 -20 08 Semaglutide: -16.7% 16 24 32 40 48 56 64 72 80 88 96 104 Time since initiation (weeks) Change in body weight in % depicts observed means since time of randomisation; trial product estimand; mean body weight: 106.0 kg Novo NordiskⓇ Semaglutide appeared to have a safe and well-tolerated profile Improvements in lipid profiles as well as C-reactive protein

View entire presentation